TABLE 1.

Commercially available pharmaceutical cocrystals.

Commercial name	API	Conformer	Improved property	References
Suglat®	Ipragliflozin	l-Prolin	Stability against hydrate formation	(Approval of Suglat tablets, kotobuki Pharmaceuticals, 2014; Kavanagh et al., 2019)
Entresto® (Drug–Drug cocrystal)	Valsartan	Sacubitril	Improved pharmacokinetics and bioavailability of valsartan	(Emami et al., 2018; “; Entresto, Highlights of prescribing information, 2015; Feng et al., 2012)
Steglatro®	Ertugliflozin	Z-Pyroglutamic acid	Improved stability	(Duggirala et al., 2019; Vasoya et al., 2019)
Depakote®	Valproic acid	Valproate sodium	Solid phase stability and less hygroscopicity	(Brittain, 2013; Kavanagh et al., 2019)
Lexapro®	Escitalopram	Oxalate	Improved stability of API	(Lexapro, 2002; Harrison et al., 2007)
Beta chlor®	Chloral hydrate	Betaine	Improved thermal stability	(O’Nolan et al., 2016; Kavanagh et al., 2019)